Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin

The American Journal of Cardiology
M ZehenderH Just


Efficacy and safety of ketanserin were studied prospectively in a randomized, double-blind trial involving 221 patients treated for hypertension or coronary artery disease, or both. Since ketanserin has been suggested to cause QTc prolongation, the incidence and severity of this effect were investigated, as was the incidence of malignant ventricular arrhythmias during Holter monitoring. After a 1-week run-in period, all patients were examined: blood pressure was measured and electrocardiograms and 24-hour Holter electrocardiograms were obtained. Two thirds of the patients (n = 147) were then randomized to receive ketanserin for 1 week (20 mg twice daily) followed by 3 weeks of 40 mg twice daily; one third of the patients (n = 74) received placebo (twice daily) for 4 weeks. After 4 weeks of treatment, blood pressure, electrocardiograms and 24-hour Holter electrocardiograms were repeated. In hypertensive patients, ketanserin significantly reduced systolic (mean reduction 17 +/- 2 mm Hg, p less than 0.0001) and diastolic blood pressure (12 +/- 1 mm Hg, p less than 0.0001) compared to baseline, and to the placebo group (p less than 0.005 for systolic and diastolic blood pressure). The QTc interval was prolonged with ketanserin (mea...Continue Reading


Jan 1, 1985·Journal of Cardiovascular Pharmacology·B Arneklo-NobinK Törnebrandt
Jan 1, 1987·Journal of Cardiovascular Pharmacology·P A van Zwieten
Jan 1, 1987·Journal of Cardiovascular Pharmacology·P A van ZwietenH N Doods
Jan 1, 1987·Journal of Cardiovascular Pharmacology·P Vanhoutte
Jan 1, 1987·Journal of Cardiovascular Pharmacology·K NademaneeB N Singh
May 1, 1986·American Heart Journal·J ManouvrierG Ducloux
Nov 1, 1983·Journal of Cardiovascular Pharmacology·D TrenkE Jähnchen
Sep 1, 1984·British Heart Journal·M J AntonaccioL F Soyka
Aug 1, 1983·British Journal of Clinical Pharmacology·T HednerG Berglund


Jun 1, 1995·Journal of Clinical Pharmacology·W H FrishmanB Shareef
Jan 1, 1990·Cardiovascular Drugs and Therapy·S T McCarthyS E Gould
Aug 1, 1990·Cardiovascular Drugs and Therapy·G C KayeA J Camm
Jan 1, 1991·Clinical and Experimental Hypertension. Part A, Theory and Practice·G S LiuY Z Tong
May 10, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·David BrasilNaranjan S Dhalla
May 23, 2000·Annals of Medicine·W H Frishman, P Grewall
Feb 24, 2004·Cardiovascular Drug Reviews·Harjot K SainiNaranjan S Dhalla

Related Concepts

Cardiac Arrhythmia
Clinical Trials
Double-Blind Method
Electrocardiographic Recorders
Hypertensive Disease
Monitoring, Physiologic
Multicenter Trials

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.